CrossRef Pan-immune-inflammation value and mortality in the US adult MASLD: a nonlinear NHANES analysis Qing Zhou, Jisu Xue, Lu Hao BMC Gastroenterology .2025;[Epub] CrossRef Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 19992018 Yanshan Yi, Li Yang Frontiers in Nutrition .2025;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease: Mechanisms, metabolic reprogramming, and therapeutic insights Wan-Qi Yang, Ling-Ling Xue, Jing-Lin Wang World Journal of Gastroenterology .2025;[Epub] CrossRef Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S
For patients with obesity or mainly seeking a weight loss injection, Wegovy is the only one approved by the FDA, while Ozempic and Rybelsus are focused more on blood sugar control
NXY-059, a failed stroke neuroprotectant, offers no protection to stem cell-derived human neurons
The study examined almost 17,000 US patients and found those prescribed semaglutide had a higher risk of NAION than those taking non-GLP-1 medications for diabetes
Invadopodium A type of ECM contact that is different from focal complexes and focal adhesions but similar to podosomes
Semaglutide is an agonist of glucagon-like peptide-1 (GLP-1) receptor that is developed to treat type 2 diabetes